Printer Friendly

1984 to 2016 Saw Increase in Age of Death for HIV-Infected; Autopsy data trends include increase in prevalence of atherosclerosis, drop in opportunistic infections.

THURSDAY, Aug. 29, 2019 (HealthDay News) -- The mean age at death increased for patients with HIV infection from 1984 to 2016, according to a study published online Aug. 28 in the Archives of Pathology & Laboratory Medicine.

Sobia Nizami, M.D., from the NYU School of Medicine in New York City, and colleagues conducted a retrospective review of autopsy records and charts to examine trends in the cause of death of HIV-infected patients who underwent autopsy at a major New York City hospital from 1984 to 2016.

The researchers identified 252 autopsies in adult patients with AIDS or HIV infection. On average, 13 autopsies were done per year prior to widespread use of highly active antiretroviral therapy (HAART) in 1984 to 1995; the average declined to 4.5 per year post-HAART. In 1984, the fitted mean age at death was 36 years and increased curvilinearly to 45 years in 2016, with a peak of 54 in 2010. From 1992 to 2016, an increase was noted in CD4+ cell counts from 6 to 62. A decrease in the proportion of AIDS-defining opportunistic infections was seen during the study period, while the frequency of nonopportunistic infections increased. There was an increase in the prevalence of atherosclerosis at autopsy, from 21 percent in 1988 to 1991 to 54 percent in 2008 to 2011.

"Autopsies can be a valuable tool in diagnosis of clinical conditions leading to death when studying trends in disease mortality," the authors write.

Abstract/Full Text (subscription or payment may be required)

COPYRIGHT 2019 HealthDay
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Physician's Briefings
Date:Aug 29, 2019
Words:251
Previous Article:New Anti-CRE Antibiotics Used for 35 Percent of Infections; Ceftazidime-avibactam, meropenem-vaborbactam, plazomicin exceeded IV polymyxins as of...
Next Article:2001 to 2016 Saw Large Increase in Mohs Surgery for Melanoma; Regional variation considerable, with more than threefold variation between regions...
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters